| Citation: |
NIE Zhimei, DOU Jianxin, DU Jin, GU Weijun, LYU Zhaohui, DOU Jingtao, MU Yiming. Irregular Menstruation-Hirsutism-Infertility: Clinical Management of Non-Classic Congenital Adrenal Hyperplasia[J]. Journal of Rare Diseases, 2023, 2(3): 420-426. DOI: 10.12376/j.issn.2097-0501.2023.03.013
|
A 38-year-old female presented with irregular menstruation and hirsutism that started at age of 16 and diagnosed with polycystic ovary syndrome at age of 29 with elevated testosterone. When treated with ethinestradiol cyproterone tablets, her menstruation returned to normal and androgen levels was not changed. At age of 38 she was referred to the hospital with infertility, a diagnosis of nonclassical 21-hydroxylase deficiency was confirmed using 17-hydroxyprogesterone, dehydroepiandrosterone-sulfate, a cosyntropin-stimulation test and genetic test. This case suggested that nonclassical congenital adrenal hyperplasia should be considered when a patient is presented with oligomenorrhea, hirsutism with hyperandrogenemia and infertility.
| [1] |
Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2018, 103(11): 4043-4088. doi: 10.1210/jc.2018-01865
|
| [2] |
中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ201810010.htm
|
| [3] |
Glintborg D, Altinok ML, Petersen KR, et al. Total testosterone levels are often more than three times elevated in patients with androgen-secreting tumours[J]. BMJ Case Rep, 2015, 2015: bcr2014204797. doi: 10.1136/bcr-2014-204797
|
| [4] |
Papadakis G, Kandaraki EA, Tseniklidi E, et al. Polycystic ovary syndrome and NC-CAH: distinct characteristics and common findings. a systematic review[J]. Front Endocrinol (Lausanne), 2019, 10: 388. doi: 10.3389/fendo.2019.00388
|
| [5] |
Wasniewska MG, Morabito LA, Baronio F, et al. Growth trajectory and adult height in children with nonclassical congenital adrenal hyperplasia[J]. Horm Res Paediatr, 2020, 93(3): 173-181. doi: 10.1159/000509548
|
| [6] |
丁颖, 田秦杰, 卢琳. 孕酮在非经典型21羟化酶缺乏症和多囊卵巢综合征鉴别诊断中的作用[J]. 生殖医学杂志, 2010, 19(4): 309-312. doi: 10.3969/j.issn.1004-3845.2010.04.005
|
| [7] |
Baskind NE, Balen AH. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome[J]. Best Pract Res Clin Obstet Gynaecol, 2016, 37: 80-97. doi: 10.1016/j.bpobgyn.2016.03.005
|
| [8] |
Pall M, Azziz R, Beires J, et al. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia[J]. Fertil Steril, 2010, 94(2): 684-689. doi: 10.1016/j.fertnstert.2009.06.025
|
| [9] |
王静, 张玲玉, 秦瑶, 等. 在育龄期不孕的高雄激素血症女性中筛查先天性肾上腺皮质增生症[J]. 中华内分泌代谢杂志, 2020, 36(3): 240-245. doi: 10.3760/cma.j.cn311282-20190703-00253
|
| [10] |
Carmina E, Rosato F, Jannì A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism[J]. J Clin Endocrinol Metab, 2006, 91(1): 2-6. doi: 10.1210/jc.2005-1457
|
| [11] |
王胜男, 夏艳洁, 许莉军, 等. 非经典型21-羟化酶缺陷症与多囊卵巢综合征的鉴别诊断分析[J]. 中华内分泌代谢杂志, 2020, 36(4): 288-293. doi: 10.3760/cma.j.cn311282-20190822-00337
|
| [12] |
聂敏, 崔铭萱, 茅江峰, 等. 孕酮对21-羟化酶缺陷症的诊断价值初步探讨[J]. 中华医学杂志, 2016, 96(48): 3866-3869. doi: 10.3760/cma.j.issn.0376-2491.2016.48.003
|
| [13] |
Rachoń D. Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome[J]. Exp Clin Endocrinol Diabetes, 2012, 120(4): 205-209. doi: 10.1055/s-0031-1299765
|
| [14] |
Goolsby MJ. AACE hyperandrogenism guidelines[J]. J Am Acad Nurse Pract, 2001, 13(11): 492-494.
|
| [15] |
戴好, 卢琳, 邢小平, 等. 中剂量地塞米松雄激素抑制试验在女性高雄激素血症中的诊断价值[J]. 中华医学杂志, 2018, 98(26): 2073-2077. doi: 10.3760/cma.j.issn.0376-2491.2018.26.003
|
| [16] |
Ambroziak U, Kępczyńska-Nyk A, Kuryłowicz A, et al. The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis[J]. Clin Endocrinol (Oxf), 2016, 84(1): 23-29. doi: 10.1111/cen.12935
|
| [17] |
Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women[J]. Hum Reprod Update, 2017, 23(5): 580-599. doi: 10.1093/humupd/dmx014
|
| [18] |
Speiser PW, Knochenhauer ES, Dewailly D, et al. A multicenter study of women with nonclassical congenital adrenal hyperplasia: relationship between genotype and phenotype[J]. Mol Genet Metab, 2000, 71(3): 527-534. doi: 10.1006/mgme.2000.3036
|
| [19] |
Livadas S, Dracopoulou M, Dastamani A, et al. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene[J]. Clin Endocrinol (Oxf), 2015, 82(4): 543-549. doi: 10.1111/cen.12543
|
| [20] |
Araújo RS, Mendonca BB, Barbosa AS, et al. Microconversion between CYP21A2 and CYP21A1P promoter regions causes the nonclassical form of 21-hydroxylase deficiency[J]. J Clin Endocrinol Metab, 2007, 92(10): 4028-4034. doi: 10.1210/jc.2006-2163
|
| [21] |
Moran C, Azziz R, Carmina E, et al. 21-hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study[J]. Am J Obstet Gynecol, 2000, 183(6): 1468-1474. doi: 10.1067/mob.2000.108020
|
| [22] |
Kohn B, Levine LS, Pollack MS, et al. Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia[J]. J Clin Endocrinol Metab, 1982, 55(5): 817-827. doi: 10.1210/jcem-55-5-817
|
| [23] |
Moran C, Azziz R, Weintrob N, et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia[J]. J Clin Endocrinol Metab, 2006, 91(9): 3451-3456. doi: 10.1210/jc.2006-0062
|
| [24] |
Bidet M, Bellanné-Chantelot C, Galand-Portier MB, et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyper-plasia due to 21-hydroxylase deficiency and 330 family members[J]. J Clin Endocrinol Metab, 2009, 94(5): 1570-1578. doi: 10.1210/jc.2008-1582
|
| [25] |
Armengaud JB, Charkaluk ML, Trivin C, et al. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche[J]. J Clin Endocrinol Metab, 2009, 94(8): 2835-2840. doi: 10.1210/jc.2009-0314
|
| [26] |
Trapp CM, Oberfield SE. Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update[J]. Steroids, 2012, 77(4): 342-346. doi: 10.1016/j.steroids.2011.12.009
|
| [27] |
Stoupa A, González-Briceño L, Pinto G, et al. Inadequate cortisol response to the tetracosactide (Synacthen) test in non-classic congenital adrenal hyperplasia: an exception to the rule?[J]. Horm Res Paediatr, 2015, 83(4): 262-267. doi: 10.1159/000369901
|
| [1] | XU Yiming, PENG Huiming, LYU Shuaijie, TONG Peijian, LI Hu, CHEN Fenyong, WANG Haibin, YANG Qi, CHEN Bin, YUAN Zhen, BI Rongxiu, FENG Jianmin, JIANG Wenxue, ZHOU Zongke, FAN Meng, LI Xiang, LEI Guanghua, WENG Xisheng. A Survey of the Current Status of Surgical Treatment of Hemophilic Osteoarthropathy in China Mainland 17 Grade A General Hospitals[J]. Journal of Rare Diseases, 2023, 2(4): 516-522. DOI: 10.12376/j.issn.2097-0501.2023.04.008 |
| [2] | YE Changxiong, SUN Jing. Development and Utilization of "One-Stop Finance Service" forRelief Fund for Hemophilia Patients[J]. Journal of Rare Diseases, 2022, 1(4): 474-478. DOI: 10.12376/j.issn.2097-0501.2022.04.019 |
| [3] | LI Shunping, DOU Lei, FANG Yunhai. Current Situation and Prospect of Pharmacoeconomic Evaluation of Hemophilia in China[J]. Journal of Rare Diseases, 2022, 1(4): 468-473. DOI: 10.12376/j.issn.2097-0501.2022.04.018 |
| [4] | ZHANG Jing, JU Mankai, ZHANG Kemin, CHEN Lingling, WANG Yuhua, ZHANG Lei, YANG Renchi, XUE Feng. A Case of Hemophilia B with Abdominal and Pelvic Pseudotumor[J]. Journal of Rare Diseases, 2022, 1(4): 456-460. DOI: 10.12376/j.issn.2097-0501.2022.04.016 |
| [5] | GUO Xinjuan, DING Xiaoling, LI Dongshuang, LI Jun. Practical Guidance for Ultrasonic Evaluation of Hemophilic Arthropathy[J]. Journal of Rare Diseases, 2022, 1(4): 449-455. DOI: 10.12376/j.issn.2097-0501.2022.04.015 |
| [6] | Hemophilia Treatment Center Collaborative Network of China. Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A[J]. Journal of Rare Diseases, 2022, 1(4): 428-434. DOI: 10.12376/j.issn.2097-0501.2022.04.011 |
| [7] | DAI Xinyue, ZHANG Lei. Status and Prospect of Gene Therapy for Hemophilia[J]. Journal of Rare Diseases, 2022, 1(4): 386-390. DOI: 10.12376/j.issn.2097-0501.2022.04.005 |
| [8] | CHENG Yan, FANG Yunhai, ZHANG Xinsheng. Current Status and Discussion of Hemophilia Aid System[J]. Journal of Rare Diseases, 2022, 1(4): 375-379. DOI: 10.12376/j.issn.2097-0501.2022.04.003 |
| [9] | XUE Feng, YANG Renchi. Establishment and Evolution of China National Hemophilia Registry[J]. Journal of Rare Diseases, 2022, 1(4): 370-374. DOI: 10.12376/j.issn.2097-0501.2022.04.002 |
| [10] | YANG Renchi. Establishment of Care System for Hemophilia in China: Current Status and Future Prospect[J]. Journal of Rare Diseases, 2022, 1(4): 365-369. DOI: 10.12376/j.issn.2097-0501.2022.04.001 |
Official account
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Author
Peer Review
Editorial Entry
Editor Work
DownLoad: